Cue Biopharma, Inc.
aTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.
Ray Sumita (Chief Legal Compliance Officer) sold 8,829 shares of Cue Biopharma, Inc. (CUE) at an average of $30.09 ($29.37–$31.13, $0.27M total) across 3 trades on 2026-08-13.
Meluzio Michael Vincent (VP, Prin. Accounting Officer) sold 5,628 shares of Cue Biopharma, Inc. (CUE) at an average of $30.09 ($29.37–$31.13, $0.17M total) across 3 trades on 2026-08-13.
Over the past 7 days, alphai's AI scored 1 news story mentioning CUE (Cue Biopharma, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CUE coverage spans corporate actions, insider activity and earnings.
In the last 30 days, CUE insiders filed 11 SEC Form 4 transactions — no purchases and 11 sales ($2.0M). The most active reporter was Lin Shao-Lee, Chief Executive Officer, with 5 filings.
New CFO may guide upcoming IND and Phase II readout execution.
The filing is a routine insider sale under a Form 4, with no stated link to company fundamentals or new guidance.
This is a routine insider open-market sale under a Form 4, with no 10b5-1 plan and no accompanying fundamental catalyst disclosed.
The filing is a new insider-sale datapoint, but it does not by itself change Cue’s fundamentals or guidance.
Near-term trading focus is likely on cash runway and the timing of CUE-221 Phase 2 readouts, alongside dilution risk from the PIPE.
alphai scores every news story that mentions CUE with an AI model for sentiment and relevance, and aggregates insider trades from Cue Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
aTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.
3 min readRay Sumita (Chief Legal Compliance Officer) sold 8,829 shares of Cue Biopharma, Inc. (CUE) at an average of $30.09 ($29.37–$31.13, $0.27M total) across 3 trades on 2026-08-13.
1 min readMeluzio Michael Vincent (VP, Prin. Accounting Officer) sold 5,628 shares of Cue Biopharma, Inc. (CUE) at an average of $30.09 ($29.37–$31.13, $0.17M total) across 3 trades on 2026-08-13.
1 min readLin Shao-Lee (Chief Executive Officer) sold 58,258 shares of Cue Biopharma, Inc. (CUE) at an average of $27.58 ($26.99–$29.48, $1.61M total) across 5 trades over 2026-08-12 to 2026-08-13.
2 min readCue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications • Completed a $50 million private placement (PIPE) to further f
6 min readCue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (c) On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) app
3 min readBiotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.
5 min readCue Biopharma (Nasdaq: CUE) appointed Dominic Borie as Chief Medical Officer and Head of R&D. The company expects Phase 2 data readout for CUE-221 by end of Q3 2026 and plans a Phase 1 trial of CUE-401 by end of Q4 2026. Cue also disclosed a $50M private placement to fund clinical development.
3 min readCue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 d123955dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of July 9, 2026, by and among Cue Biopharma, Inc., a Delaware corporation (the “ Company ”), and each of the purchasers liste
6 min readCue Biopharma (CUE) said it agreed to a private placement of 1,418,071 shares at $33.21 each, plus pre-funded warrants for up to 87,500 shares at $33.209 per warrant, for about $50 million gross proceeds. The deal is expected to close around July 13, 2026. Proceeds will fund clinical development and general corporate use.
3 min read
